Research & Invest
Investor, Institutional Asset Management Background
Aehr Test Systems is priced like a SaaS company while running a low-margin equipment business, worse than 1999. A roughly $60 million revenue company trades at $3 billion, about 20 times sales, on $40 million of bookings and a $41 million follow-on. A wafer-level burn-in business cannot reach $1 billion in revenue in one to three years, and even then it would merit about 3x sales. CEO Gayn Erickson's past stock sales preceded steep declines four to nine months later. x.com x.com
Aehr Test Systems is key to AI manufacturing and can even be a bottleneck, but at almost 20x revenue through 2028 at the current price, it is stratospherically priced. The risk is giant if something goes wrong for the company or for the AI ramp, and even a slowdown could be deadly at such high valuations. Tech moats are not the same as financial moats. x.com
Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.com
Aehr Test Systems is an upper-tier opportunity for anyone who believes the AI build-out is still in its early innings, after giving back nearly all of its 40% post-earnings gain. Guidance of about $140M at the midpoint implies roughly 170% growth over FY26 at about 20x sales, not cheap but a big opportunity alongside a $100M backlog. Many names map back to Aehr. x.com
Aehr Test Systems' valuation looks ahead of its fundamentals after a strong turnaround quarter. Q4 FY2026 revenue rose 33% to $18.8 million with a return to GAAP profit, bookings hit a record $60.7 million and effective backlog topped $100.6 million. FY2027 guidance of $130-150 million implies 160-200% growth, so the post-earnings run prices in high expectations that depend on shipping FOX-XP systems on schedule without margin erosion. TRT is preferred for now. x.com x.com
Aehr Test Systems' FY2027 guidance for 160–200% revenue growth is conservative, built on backlog, pending deals and pilot programs, and it should beat the top end by at least 15–20%, implying about 245% growth. That gives the stock a shot at $150-plus within 12 months, especially if it is on track for $300 million-plus of FY2028 revenue; FY2029 revenue could reach $474 million. The post-earnings fade that erased most of the gains is an opportunity. x.com x.com
Aehr Test Systems' thesis strengthened with its best report ever, though the stock's risk/reward is now impaired. The most important disclosure was that its lead AI customer has eliminated system-level burn-in and moved production entirely to Aehr's wafer-level systems. FY27 guidance of $130-150M far exceeded the $85M consensus. x.com